mice by using an isolated perfused working heart system, controlling for both preload and afterload, and using identical concentrations of insulin, fatty acids, and glucose in the absence of supplemental SEE PAGE 347 
. Notably, the improvements in primary outcomes in the EMPA-REG OUTCOMES trial occurred within the first 2 to 3 months of the trial. These striking results have raised a number of questions about the potential mechanism of action whereby empagliflozin, a renal sodium glucose transport (SGLT) inhibitor, reduces heart failure endpoints. A number of mechanisms, both cardiac and extracardiac, have been proposed including enhanced diuretic efficiency, renal protective effects, enhanced cardiac substrate metabolism, and decreased vascular stiffness. However, the specific mechanism responsible for the striking effects of empagliflozin on CV outcomes is not known (2) . Accordingly, the paper by Science author instructions page. and is generally 10-to 100-fold higher than the expression of SGLT1 in the same tissues, except for the heart, where SGLT1 mRNA is highly expressed.
T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R T H E C C B Y -N C -N D L I C E N S E ( h t t p :
Relevant to the current study, SGLT1 mRNA and protein have been detected in cardiac myocytes (4, 5) , were conducted in nondiabetic animals, which suggests that prevention of glucotoxicity by SGLT2 inhibition is not a potential mechanism. Moreover, given that the ex vivo studies were performed in the absence of exogenous ketone substrates, the observed effects were likely not due to altered ketone metabolism, one of the metabolic mechanisms proposed for SGLT2i by empagliflozin; however, this study does not formally exclude a potential role for empagliflozin-mediated alterations in endogenous ketone metabolism. Although SGLT2 expression is relatively low in the heart, one cannot exclude the possibility that the cardiac autonomous effects noted in this study could be due to a direct effect of glucose transport or related transport mechanisms. In this regard, it is interesting to note that empagliflozin has been shown to directly inhibit the Na þ /H þ exchanger (NHE) in isolated cardiac myocytes (6) . Empagliflozin and the Prevention of Heart Failure A U G U S T 2 0 1 7 : 3 5 5 -7 unique pharmacological profile of SGLT2 inhibitors places them at the intersection of metabolic, hemodynamic, neurohumoral, and vascular endothelial pathways that impact the heart and the kidney, all of which are important in the treatment of heart failure, particularly heart failure with a reduced ejection fraction, for which there are no currently U.S.
Food and Drug Administration-approved therapies.
The exciting study by Byrne et 
